

- **Name:** Ramaprasad Srinivasan, M.D., Ph.D.
- **Current Position & Affiliation:** Senior Investigator and Head, Molecular Cancer Section, Urologic Oncology Branch
Deputy Director, Center for Cancer Research
National Cancer Institute
National Institutes of Health
- **Country:** USA
-

• **Educational Background:**

- 1999 – 2003 Oncology/Hematology Fellow, National Institutes of Health, National Cancer Institute and National Heart Lung and Blood Institute
- 1997 – 1999 Resident PGY2-3, University of Texas Health Science Center, Houston, TX, Department of Internal Medicine
- 1996 – 1997 Resident PGY1, State University of New York at Stony Brook, N.Y. Department Of Internal Medicine
- 1991 – 1996 Ph.D., MD Anderson Cancer Center University of Texas/Graduate School of Biomedical Sciences, Houston, TX
- 1985 – 1991 M.B, B.S. Bangalore Medical College, Bangalore, India

• **Professional Experience:**

- 2024- Present Deputy Director, Center for Cancer Research
Senior Investigator and Head, Molecular Cancer Section,
Urologic Oncology Branch, National Cancer Institute
- 2023- 2024 Senior Investigator and Head, Molecular Cancer Section, Urologic Oncology Branch, National Cancer Institute
- 2016- 2023 Investigator and Head, Molecular Cancer Section, Urologic Oncology Branch, National Cancer Institute
- 2012 - 2016 Head, Molecular Cancer Section, Urologic Oncology Branch National Cancer Institute
- 2005 – 2012 Staff Clinician, Urologic Oncology Branch, National Cancer Institute
- 2003 – 2005 Senior Clinical Fellow, Urologic Oncology Branch, National Cancer Institute

• **Professional Organizations:**

Academic Society Membership:

American Association for Cancer Research, American Society of Clinical Oncology

Committees and Boards:

Scientific Community Activities:

Academic appointments

Chair, Protocol Scientific Review Committee, Center for Cancer Research, NCI (2017-Present)

Chair, UOB Protocol Scientific Review Committee (2012-Present)

Participation in Extramural Committees and Interest Groups

Member, CCR Clinical Tenure Review Panel (CTRP), (2023 – Present)

Member, AACR-NCI-EORTC Scientific Committee, (2022 – Present)

Member, TCGA Analysis Working Group on Papillary Kidney Cancer

Member, PDQ Cancer Genetics Editorial Board (2014-Present)

Member, PDQ Kidney Cancer Genetics Working Group (2014-Present)

Member, Editorial Board, Journal of Kidney Cancer and VHL (2016-Present)
2016 Genitourinary Symposium Program Committee (2016)
Specialty Editor, GU ASCO/Cancer.net GU Panel (2016-Present)
Associate Editor, Clinical Genitourinary Cancer (2019-Present)
Member, CMDRP-Kidney Cancer Research Program (2019-Present)
Editorial Board Member, BMC Cancer, (2020-Present)
Associate Editor for Genitourinary Malignancies, Frontiers in Oncology

• Main Scientific Publications:

1. **Srinivasan R**, Gurram S, Singer EA, Sidana A, Al Harthy M, Ball MW, Friend JC, Mac L, Purcell E, Vocke CD, Ricketts CJ, Kong HH, Cowen EW, Malayeri AA, Shih JH, Merino MJ, Linehan WM. Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. *N Engl J Med*. 2025 Jun 19;392(23):2346-2356. doi: 10.1056/NEJMoa2200900. PMID: 40532152.
2. Belzutifan (MK-6482) for von Hippel-Lindau Disease-associated renal cell carcinoma. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SH, Thamake S, Park EK, Perini RF, Linehan WM, **Srinivasan R**. *N Engl J Med*. 385: 2036-2046, 2021.
3. **Srinivasan R**, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Iversen AB, Cornell J, Perini RF, Liu Y, Linehan WM, Jonasch E. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. *Lancet Oncol*. 2025 May;26(5):571-582. doi: 10.1016/S1470-2045(25)00099-3. Epub 2025 Apr 12. Erratum in: *Lancet Oncol*. 2025 Jul;26(7):e349. doi: 10.1016/S1470-2045(25)00354-7. PMID: 40228516; PMCID: PMC12050119.
4. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Pahwa R, Dubhashi J, Singh A, Jailwala P, Lobanov A, Thomas CJ, Ceribelli M, Wilson K, Ricketts CJ, Vocke CD, Wells C, Bottaro DP, Linehan WM, Neckers L, **Srinivasan R**. *J Exp Clin Cancer Res*. 41(1): 208, 2022.
5. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, **Srinivasan R**. *J Clin Oncol*. 31(2)/ Jan 10: 181-186, 2013.
6. Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. Crooks DR, Maio N, Lang M, Ricketts CJ, Vocke CD, Gurram S, Turan S, Kim YY, Cawthon GM, Sohelian F, De Val N, Pfeiffer RM, Jailwala P, Tandon M, Tran B, Fan TW, Lane AN, Ried T, Wangsa D, Malayeri AA, Merino MJ, Yang Y, Meier JL, Ball MW, Rouault TA, **Srinivasan R**, Linehan WM. *Sci Signal*. 14(664); Jan 5: 2021.

7. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion. Kauffman EC, Lang M, Rais-Bahrami S, Gupta GN, Wei D, Yang Y, Sourbier C, **Srinivasan R**. BMC Cancer. 19(1): 917, 2019.